NIAID Archives - EverGlade Consulting

NIAID

medical countermeasures for biodefense and infectious diseases

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease

HHS-NIH-NIAID-BAA2025-1 The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has released the Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1. This announcement presents an exciting opportunity for researchers, organizations, and industry leaders to contribute to critical biomedical and biodefense initiatives. […]

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease Read More »

antimicrobial-resistant (AMR) pathogens and viruses

NIAID Omnibus Broad Agency Announcement (BAA)

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through

NIAID Omnibus Broad Agency Announcement (BAA) Read More »

Scroll to Top
Flask with blue light

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.